Brain–blood ratio: implications in brain drug delivery

Bibliography

• Alvijeh MS, Chishty M, Qaiser et al.Palmer AM. Drug Metabolism and Pharmacokinetics, the Blood-Brain Barrier, and Central Nervous System Drug Discovery. NeuroRx 2005;2:554-71
   PubMedGoogle Scholar
• Available from: http://www.wikinvest.com/wiki/Central_Nervous_System_Drug_Market [Last accessed 26 Feb 2015]
   Google Scholar
• Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713-31
   PubMed Web of Science ®Google Scholar
• Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000;89:1371-88
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Read K, Begley DJ, et al. Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction. J Pharmacol Exp Ther 2007;322:205-13
   PubMed Web of Science ®Google Scholar
• Dagenais C, Rousselle C, Pollack GM, et al. Development of an in situ mouse brain perfusion model and its application tomdr1aPglycoprotein-deficient mice. J Cereb Blood Flow Metab 2000;20:381-6
   PubMed Web of Science ®Google Scholar
• Feng MR. Assessment of blood–brain barrier penetration: in silico, in vitro and in vivo. Curr Drug Metab 2002;3:647-57
   PubMed Web of Science ®Google Scholar
• Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab 2006;7:183-203
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 2002;1:131-9
   PubMed Web of Science ®Google Scholar
• Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004;10:1295-312
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005;2:86-98
   PubMedGoogle Scholar
• Sawchuk RJ, Elmquist WF. Microdialysis in the study of drug transporters in the CNS. Adv Drug Deliv Rev 2000;45:295-307
   PubMed Web of Science ®Google Scholar
• Mano Y, Higuchi S, Kamimura H. Investigation of the high partition of YM992, a novel antidepressant, in rat brain- in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm Drug Dispos 2002;23:351-60
   PubMed Web of Science ®Google Scholar
• Reichel A. Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept. Chem Biodiverse 2009;6:2030-49
   PubMed Web of Science ®Google Scholar
• Kulkarni AD, Vanjari YH, Sancheti KH, et al. Nanotechnology-mediated nose to brain drug delivery for Parkinson’s disease: a mini review. J Drug Target 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Jouyban A, Soltani S. Blood Brain Barrier Permeation, Toxicity and Drug Testing, Prof. Bill Acree (Ed.), ISBN: 978-953-51-0004-1, InTech. Available from: http://www.intechopen.com/books/toxicity-and-drug-testing/blood-brain-barrier-penetration [Last accessed 02 March 2015]
   Google Scholar
• Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: Molecular parameters governing passive diffusion. J Membr Biol 1998;165:201-11
   PubMed Web of Science ®Google Scholar
• Kerns EH, Di L. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. Academic Press; London, UK: 2008
   Google Scholar
• Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12:54-61
   PubMed Web of Science ®Google Scholar
• Ueno M. Mechanisms of the penetration of blood-borne substances into the brain. Curr Neuropharmacol 2009;7:142-9
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005;76:22-76
   PubMed Web of Science ®Google Scholar
• Sharma D, Sharma RK, Sharma N, et al. Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles. AAPS PharSciTech 2015; Epub ahead of print
   Web of Science ®Google Scholar
• Jain R, Nabar S, Dandekar P, Patravale V. Micellar Nanocarriers: Potential Nose-to-Brain Delivery of Zolmitriptan as Novel Migraine Therapy. Pharm Res 2010;27:655-64
   PubMed Web of Science ®Google Scholar
• Salunkhe SS, Bhatia NM, Bhatia MS. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain. Drug Deliv 2014; Epub ahead of print
   PubMedGoogle Scholar
• Md S, Khan RA, Mustafa G, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model. Eur J Pharm Biopharm 2013;48:393-405
   Web of Science ®Google Scholar
• Kumar M, Misra A, Babbar AK, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008;358:285-91
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 2013;10:957-72
   PubMed Web of Science ®Google Scholar
• Patel RB, Patel MR, Bhatt KK, et al. Microemulsion-based drug delivery system for transnasal delivery of Carbamazepine: preliminary brain-targeting study. Drug Deliv 2014; Epub ahead of print
   Google Scholar
• Li J, Feng L, Fan L, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011;32:4943-50
   PubMed Web of Science ®Google Scholar
• Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug MetabDispos 2000;28:655-60
   PubMed Web of Science ®Google Scholar
• Yue P, He L, Qiu S, et al. OX26/CTX-conjugated PEGylated liposomes as a dual-targeting gene delivery system for brain glioma. Mol Cancer 2014;13:191-203
   PubMed Web of Science ®Google Scholar
• Foley CP, Rubin DG, Santillan A, et al. Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption. J Control Release 2014;196:71-8
   PubMed Web of Science ®Google Scholar
• Doran A, Obach RC, Smith BJ, et al. The impact of p-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/1b knockout mouse model. Drug Metab Dispos 2005;33:165-74
   PubMed Web of Science ®Google Scholar
• Gillette JR. Factors affecting drug metabolism. Ann NY Acad Sci 1971;179:43-66
   PubMed Web of Science ®Google Scholar
• Maurer TS, DeBartolo DB, Tess DA, Scott DO. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005;33:175-81
   PubMed Web of Science ®Google Scholar